|
C14ORF21 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.18329999998501E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.5414399999969E-05 |
| Normal-vs-Stage2 |
1.783570E-02 |
| Normal-vs-Stage3 |
1.94893999999612E-05 |
| Normal-vs-Stage4 |
1.91626999999084E-05 |
| Stage1-vs-Stage2 |
2.960600E-01 |
| Stage1-vs-Stage3 |
8.816800E-01 |
| Stage1-vs-Stage4 |
3.657800E-01 |
| Stage2-vs-Stage3 |
2.772600E-01 |
| Stage2-vs-Stage4 |
1.510970E-01 |
| Stage3-vs-Stage4 |
5.066800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.70318999999086E-05 |
| Normal-vs-AfricanAmerican |
2.671500E-02 |
| Normal-vs-Asian |
2.232800E-04 |
| Caucasian-vs-AfricanAmerican |
4.955800E-01 |
| Caucasian-vs-Asian |
5.758800E-01 |
| AfricanAmerican-vs-Asian |
2.918800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.67040000112573E-08 |
| Normal-vs-Female |
4.11580000000411E-05 |
| Male-vs-Female |
1.909760E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.187350E-04 |
| Normal-vs-Age(41-60Yrs) |
1.64821999999454E-05 |
| Normal-vs-Age(61-80Yrs) |
1.7126399999956E-05 |
| Normal-vs-Age(81-100Yrs) |
3.496100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.191800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.843400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.881600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.863400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.430800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.721200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.129400E-01 |
| Classical-VS-Follicular |
1.116250E-03 |
| Classical-VS-Other |
3.291900E-02 |
| Classical-VS-Normal |
2.621400E-04 |
| Tall-VS-Follicular |
4.110800E-01 |
| Tall-VS-Other |
9.733600E-02 |
| Tall-VS-Normal |
5.386600E-04 |
| Follicular-VS-Other |
3.180400E-01 |
| Follicular-VS-Normal |
2.11799999982887E-07 |
| Other-VS-Normal |
1.164080E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.86017000000094E-05 |
| Normal-vs-N1 |
1.67635999999138E-05 |
| N0-vs-N1 |
3.228800E-01 |
|
|
